Zealand, Protagonist to develop peptide drug
Zealand Pharma and Protagonist Therapeutics have joined forces to identify,optimise and develop disulfide-rich peptides (DRPs) with the therapeutic potential to provide better treatment for patients in defined, non-disclosed disease areas.
As part of the collaboration Protagonist will provide a valid and proprietary technology platform for the discovery and optimisation of novel DRPs (disulfide rich peptides).
Zealand Pharma will be responsible for preclinical and clinical drug development of DRPs.
The trial will be financed by Zealand Pharma, which will hold rights to new DRP drug candidates generating from the agreement.
As part of the agreement Protagonist will receive share in Zealand Pharma's product sales and revenues in addition to advance payment and revenue depending on the achievement of pre-defined discovery and development milestones.
Zealand Pharma Chief Scientific Officer Christian Grondahl said, "Protagonist has developed a proprietary peptide technology platform with unique attributes that complements and leverages our internal peptide drug discovery and development capabilities."
Protagonist Therapeutics President and CEO Dinesh V. Patel said,"Zealand Pharma has an impressive track record of developing peptide based NCEs (new chemical entities) and we look forward to applying our unique technology platform to their specific research objectives."